

CURRICULUM VITAE

Dr. Chryssi Hatzoglou



Professor of Medical Physiology

Department of Physiology

Faculty of Medicine

University of Thessaly, Greece

October 2019

PERSONAL DATA

Name: **Chryssi Hatzoglou**
Address: Department of Physiology, Faculty of Medicine
School of Health Sciences
University of Thessaly
Panepistimiou 3 (Viopolis)
41500 Larissa, Greece
Tel: +302410 685557, Fax: +302410 685555, e-mail: chatz@med.uth.gr

PROFESSIONAL DATA

2017-Present **Professor of Medical Physiology:** Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece.
2014-Present **Director of the Department of Physiology:** Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece.
2013-Present **Associate Professor of Medical Physiology:** Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece.
2004-Present **Director of the Smoking Cessation Center:** Department of Respiratory Medicine, University Hospital of Larissa, Greece.
2008-2013 **Assistant Professor of Medical Physiology:** Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece.
2003-2008 **Lecturer of Medical Physiology:** Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece.
2004-2016 **Deputy Coordinator of General Practice Residency:** University Hospital of Larissa, Greece.
2002-2003 **Consultant of General Practice:** Health Center of Kassandreia, Chalkidiki, Greece.
2001-2002 **Private Practice:** Prevention Clinic of the Greek Agricultural Bank, Larissa, Greece.
1996-2000 **Resident of General Practice:** General Hospital of Larissa, Larissa, Greece.
1991-1992 **Registered Nurse:** University General Hospital of Herakleion, Crete, Greece.

EDUCATION

1997-2002 **PhD in Physiology:** Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece.
Thesis Title: «Physiology of Pleural Cavity: Effects of amiloride, ouabain, SNP, 17beta-Estradiol and Progesterone in Pleural Fluid Turnover».
Advisor: Paschalis-Adam Molyvdas, M.D., D.Sc.
2001 **Certificate of Completion of General Practice Residency.**
1996-2000 **Resident of General Practice:** General Hospital of Larissa, Greece.
1991-1996 **MD:** School of Medicine, University of Crete, Greece.
1986-1990 **BSc in Nursing:** Nursing Department, School of Health and Welfare Professions, Technological Educational Institute of Crete, Greece.

TEACHING ACTIVITIES

Scientific Coordinator of Undergraduate Courses

2011-Present «Integrative Systems Physiology»: Lectures and practicals to the 2nd Year Medical students of the Faculty of Medicine, School of Health Sciences, University of Thessaly.

2010-Present «Smoking»: Lectures and practicals to the students of the Faculty of Medicine, School of Health Sciences, University of Thessaly.

Scientific Coordinator of Postgraduate Courses

2014-Present Coordinator of Master Theses in the Master of Science «Exercise, Ergospirometry, and Rehabilitation», University of Thessaly.

2012-Present «Smoking: Public Health Impact and cessation methods»: Master of Science in «Primary Health Care», Faculty of Medicine, University of Thessaly.

2012-Present «Alternative – Complementary Methods of Therapy»: Master of Science in «Primary Health Care», Faculty of Medicine, University of Thessaly.

2012-Present «Addiction, Focus on Smoking»: Master of Science in «Mental Health», Nursing Department, School of Health and Welfare Professions, Technological Educational Institute of Larissa, Greece.

2011-Present Coordinator of Diploma Theses in the Master of Science «Primary Health Care», Faculty of Medicine, University of Thessaly.

2009-2011 «Membrane Biophysics»: Lectures and practicals in the Master of Science «Clinical Applications of Molecular Medicine», Faculty of Medicine, University of Thessaly.

2006-2011 Coordinator of Practicum in the Master of Science «Primary Health Care»: Faculty of Medicine, University of Thessaly.

Teaching in Undergraduate Courses

2011-Present «Integrative Systems Physiology»: Lectures and practicals to the 2nd Year Medical students of the Faculty of Medicine, University of Thessaly.

2003-Present «Pathophysiology I»: Lectures to the 3rd Year Medical students of the Faculty of Medicine, University of Thessaly.

2006-2010 «Medical Communication»: Lectures and practicals to the 3rd Year Medical students of the Faculty of Medicine, University of Thessaly.

2003-2010 «Medical Physiology I, II, III»: Lectures and practicals to the 1st and 2nd Year Medical students of the Faculty of Medicine, University of Thessaly.

2001-2002 «Social and Preventive Medicine»: Lectures to the 4th Year Medical students of the Faculty of Medicine, University of Thessaly.

2000-2002 «Pathophysiology»: Lectures to the 3rd Year Medical students of the Department of Medical Biochemistry, School of Medicine, University of Thessaly.

Teaching in Postgraduate Courses

2018- Present «Membrane Physiology»: Lectures in the Master of Science «Clinical Applications of Molecular Medicine», Faculty of Medicine, University of Thessaly.

2016- Present «Physiology-Pathophysiology of Respiration», Internal Pathology Nursing Residency Program, University Hospital of Larissa, Greece.

2016- Present «Anatomy – Physiology of Central Nervous System», Internal Pathology Nursing Residency Program, University Hospital of Larissa, Greece.

- 2016- Present «Physiology», Master of Science “Management of aging and chronic diseases”, Hellenic Open University.
- 2004-2015 «Membrane Biophysics»: Lectures and practical to the students of the Master of Science «Clinical Applications of Molecular Medicine», Faculty of Medicine, University of Thessaly.
- 2003-2019 Grand Rounds, Department of Respiratory Medicine, University General Hospital of Larissa, Greece.
- 2010-2012 «Mechanisms of Biological Membranes Permeability. The Pleura Model», Lectures to the students of the Master of Science «Molecular and Applied Physiology», Department of Medicine, University of Athens.
- 2009-2013 «Prevention of Respiratory Disorders via Exercise»: Lectures to the students of the Master of Science «Exercise and Health», Department of Physical Education and Sport Science, University of Thessaly.
- 2010-2011 «Home Care»: Lectures to the students of the Master of Science «Primary Health Care», Faculty of Medicine, University of Thessaly.
- 2010-2011 «Complementary Methods of Therapy»: Lectures to the students of the Master of Science in «Primary Health Care», Faculty of Medicine, University of Thessaly.
- 2004-2005 «Emergency Respiratory Disorders»: Lectures to the students of the Postgraduate Programme «Emergency Nursing», Nursing Department, School of Health and Welfare Professions, Technological Educational Institute of Larissa, Greece.
- 2003-2016 Grand Rounds in General Practice Residency. University Hospital of Larissa, Greece.

ADVISORY COMMITTEE MEMBERSHIP IN DOCTORAL AND MASTER THESIS

Thesis advisor of PhD students:

1. E. Apostolidou (2008-2012), Thesis Title: «Effect of metalloproteinases in pleura permeability».
2. V. Konstadikaki (2009-2015), Thesis Title: «Comparison of the methods for early detection of COPD cases in Primary Health Care».
3. Z. Arsenopoulou (2013-2017), Thesis Title: «Effect of silver nanoparticles in sheep’s pleura permeability».
4. V. Peppas (2013-Present), Thesis Title: «Effect of the osmotic stress in pleura permeability».

Member of Doctoral Thesis Advisory Committee in 63 completed PhD Theses.

Advisor of postgraduate Master theses in 26 students

Member of Master Thesis Advisory Committee in 90 theses.

Advisor of undergraduate thesis in 1 student.

Member of Undergraduate thesis Advisory Committee in 2 theses.

RESEARCH INTERESTS

- Mesothelial cells and Mesothelial membranes.
- Pleural Effusions.
- Mesothelioma.
- Smoking.
- Copd.

AWARDS

1. Award for the Best Publication of the Department of Respiratory Medicine for the period 1999-2019, for the paper «In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes. Papazoglou ED, Jagirdar RM, Kouliou OA, Pitaraki E, Hatzoglou C, Gourgoulisanis KI, Zarogiannis SG. *Cancers*. 27;11(10), 2019». Annual Hellenic Conference “Days of Respiratory & Intensive Care Medicine”Volos 2019.
2. Prize for Oral Presentation. 21st National Conference of Nephrology, Delphoi, Greece, 2019.
3. 2nd Prize of Best Poster Presentation. 27th National Conference of Chest Diseases, Athens, Greece, 2018.
4. Prize for Oral Presentation. 19th National Conference of Nephrology, Kalamata, Greece, 2016.
5. Prize for Oral Presentation. 2nd National Conference of Mental Health in Primary Health Care, Athens, Greece, 2014.
6. 1st Prize of Best Research Study. 20th National Conference of Chest Diseases, Athens, Greece, 2011.
7. 1st Prize of Best Research Study. 19th National Conference of Chest Diseases, Rodos, Greece, 2010.
8. 1st Prize of Best Poster Presentation. 14th National Conference of Chest Diseases, Thessaloniki, Greece, 2005.
9. 1st Prize of Best Basic Research Study. 32nd Hellenic Medical Conference, Athens, Greece, 2006.
10. 1st Prize of Best Oral Presentation. 13th National Conference of Chest Diseases, Patra, Greece, 2004.
11. 2nd Prize of Best Research Study. 13th National Conference of Chest Diseases, Patra, Greece, 2004.
12. 2nd Prize of Best Research Study. 11th National Conference of Chest Diseases, Thessaloniki, Greece, 2001.

PUBLICATIONS

Published Papers in International Peer-Review Journals

Total Number of Publications: 99

Total Impact Factor: 304.6665

Citations: 900

H-Index: 17

Basic Research Papers (Number: 64, Impact Factor: 137.992, Citations: 607)

1. **In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.**
Papazoglou ED, Jagirdar RM, Kouliou OA, Pitaraki E, **Hatzoglou C**, Gourgoulisanis KI, Zarogiannis SG.
Cancers (Basel). 27;11(10), 2019. (Impact Factor=6.162)
2. **Pleural Effusion IL-33/sST2 Levels and Effects of Low and High IL-33/sST2 Levels on Human Mesothelial Cell Adhesion and Migration.**
Kotsiou OS, Jagirdar RM, Papazoglou ED, **Hatzoglou C**, Gourgoulisanis KI, Zarogiannis SG.
Inflammation. 19. doi: 10.1007/s10753-019-01070-6, 2019. (Impact Factor=2.939)

3. **In-Depth Bioinformatic Study of the CLDN16 Gene and Protein: Prediction of Subcellular Localization to Mitochondria.**
Rouka E, Liakopoulos V, Gourgoulisanis KI, **Hatzoglou C**, Zarogiannis SG.
Medicina (Kaunas). 26;55(8), 2019. (Impact Factor=1.467)
4. **2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.**
Gerogianni I, Pitaraki E, Jagirdar RM, Kouliou O, Giannakou L, Giannopoulos S, Papazoglou E, **Hatzoglou C**, Gourgoulisanis KI, Zarogiannis SG.
Anticancer Res. 2019 Jul;39(7):3809-3814. (Impact Factor=1.865, Citations=1)
5. **Benign Pleural Mesothelial Cells Have Higher Osmotic Water Permeability than Malignant Pleural Mesothelioma Cells and Differentially Respond to Hyperosmolality.**
Katkova LE, Baturina GS, Bondar AA, Jagirdar RM, **Hatzoglou C**, Gourgoulisanis KI, Solenov EI, Zarogiannis SG.
Cell Physiol Biochem. 52(4):869-878, 2019. (Impact Factor=5.5)
6. **In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma.**
Rouka E, Beltsios E, Goundaroulis D, Vavougiou GD, Solenov EI, **Hatzoglou C**, Gourgoulisanis KI, Zarogiannis SG.
Medicina. 12;55(6), 2019. (Impact Factor=1.467)
7. **Silver Nanoparticles Alter Cell Adhesion and Proliferation of Sheep Primary Mesothelial Cells.**
Arsenopoulou ZV, Taitzoglou IA, Molyvdas PA, Gourgoulisanis KI, **Hatzoglou C**, Zarogiannis SG.
In Vivo. 32(1):109-112, 2018. (Impact Factor=1.116)
8. **Silver nanoparticles alter the permeability of sheep pleura and of sheep and human pleural mesothelial cell monolayers.**
Arsenopoulou ZV, Taitzoglou IA, Molyvdas PA, Gourgoulisanis KI, **Hatzoglou C**, Zarogiannis SG.
Environ Toxicol Pharmacol. 50:212-215, 2017. (Impact Factor=3.061, Citations=4)
9. **Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.**
Rouka E, Vavougiou GD, Solenov EI, Gourgoulisanis KI, **Hatzoglou C**, Zarogiannis SG.
Front Physiol. 21;8:156, 2017. (Impact Factor=3.201, Citations=2)
10. **Systematic review and meta-analysis of vascular endothelial growth factor (VEGF) as a biomarker for malignant pleural effusions.**
Fafliora E, **Hatzoglou C**, Gourgoulisanis KI, Zarogiannis S.
Physiological Reports. 4 (24), 2016. (Citations=8)
11. **Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent.**
Jagirdar RM, Apostolidou E, Molyvdas PA, Gourgoulisanis KI, **Hatzoglou C**, Zarogiannis SG.
Am J Physiol Lung Cell Mol Physiol. 15;310(6):L489-L495, 2016. (Impact Factor=4.060, Citations=13)
12. **Transcriptional over-expression of chloride intracellular channels 3 and 4 in malignant pleural mesothelioma.**

- Tasiopoulou V, Magouliotis D, Solenov EI, Vavougiou G, Molyvdas PA, Gourgoulisian KI, **Hatzoglou C**, Zarogiannis SG.
Comput Biol Chem. 59:111-116, 2015. (Impact Factor=1.581, Citations=8)
13. **Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.**
Vavougiou GD, Solenov EI, **Hatzoglou C**, Baturina GS, Katkova LE, Molyvdas PA, Gourgoulisian KI, Zarogiannis SG.
Am J Physiol Lung Cell Mol Physiol. 1;309(7):L677-L686, 2015. (Impact Factor=4.060, Citations=29)
 14. **Airways microbiota: Hidden Trojan horses in asbestos exposed individuals?**
Magouliotis DE, Tasiopoulou VS, Molyvdas PA, Gourgoulisian KI, **Hatzoglou C**, Zarogiannis SG.
Med Hypotheses. 83(5):537-540, 2014. (Impact Factor=1.322, Citations=2)
 15. **VEGF increases the permeability of sheep pleura ex vivo through VEGFR2 stimulation.**
Peppas VI, Arsenopoulou ZV, Zarogiannis SG, Deligiorgi T, Jagirdar R, Makantasis I, Stefanidis I, Liakopoulos V, Molyvdas PA, Gourgoulisian KI, **Hatzoglou C**.
Cytokine. 69(2):284-288, 2014. (Impact Factor=3.078, Citations=4)
 16. **Role of Histamine in Altering Fluid Recycling in Normaland Post-Traumatic Rabbit Peritoneum.**
Kouritas VK, Tepetes K, Spyridakis M, Theodosopoulou KV, Gourgoulisian KI, Molyvdas PA, **Hatzoglou C**.
Inflammation. 37(2):534-541, 2014. (Impact Factor=2.939, Citations=1)
 17. **Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma.**
Jagirdar R, Solenov EI, **Hatzoglou C**, Molyvdas PA, Gourgoulisian KI, Zarogiannis SG.
Gene. 15;517(1):99-105, 2013. (Impact Factor=2.638, Citations=14)
 18. **Endothelin-1 Acutely Reduces the Permeability of Visceral Sheep Peritoneum In Vitro Through Both Endothelin-A and Endothelin-B Receptors.**
Kourti P, Zarogiannis SG, Liakopoulos V, Karioti A, Eleftheriadis T, **Hatzoglou C**, Gourgoulisian K, Molyvdas PA, Stefanidis I.
Artif Organs. 37(3):308-12, 2013. (Impact Factor=2.379, Citations=5)
 19. **IGF-1 alters the human parietal pleural electrochemical profile by inhibiting ion trans-cellular transportation after interaction with its receptor.**
Kouritas VK, Ioannou M, Desimonas N, Gourgoulisian KI, Molyvdas PA, **Hatzoglou C**.
Growth Horm. IGF Res. 23(1-2):8-12, 2013. (Impact Factor=2.167, Citations=1)
 20. **Pleural fluid protein is inversely correlated with age in uncomplicated parapneumonic pleural effusions.**
Zarogiannis SG, Tsilioni I, **Hatzoglou C**, Molyvdas PA, Gourgoulisian KI.
Clin Biochem. 46(4-5):378-380, 2013. (Impact Factor=2.430, Citations=6)
 21. **Matrix metalloproteinases 2 and 9 reduce epithelial sodium channel (ENaC) activity at pleural mesothelium.**
Apostolidou E, Gourgoulisian K, Molyvdas PA, **Hatzoglou C**.
Journal of Physiology and Pathophysiology. 4(1):7-10, 2013.
 22. **Nonsteroidal anti-inflammatory drugs (NSAIDs) alter the human mesothelial pleural permeability via ion cellular transportation by inhibiting prostaglandin synthesis.**

- Kouritas V, Zisis C, Bellenis I, Gourgoulianis K, Molyvdas PA, **Hatzoglou C**. **Respiration**. 84(1):62-68, 2012. (Impact Factor= 2.935, Citations=4)
23. **Matrix metalloproteinases 2 and 9 increase permeability of sheep pleura in vitro.**
Apostolidou E, Paraskeva E, Gourgoulianis K, Molyvdas PA, **Hatzoglou C**. **BMC Physiology**. 12(1):2, 2012. (Citations=9)
24. **Permeability of the arachnoid and pia mater. The role of ion channels in the leptomeningeal physiology.**
Filippidis AS, Zarogiannis SG, Ioannou M, Gourgoulianis K, Molyvdas PA, **Hatzoglou C**. **Childs Nerv Syst**. 28(4):533-40, 2012. (Impact Factor=1.327, Citations=3)
25. **Salbutamol modulation of ion transport in sheep parietal pleura is protein dependent.**
S. Zarogiannis, A. Filippidis, **C. Hatzoglou**, P. A. Molyvdas, K. Gourgoulianis. **Biol. Pharm. Bull**. 34(12): 1874-1876, 2011. (Impact Factor=1.694, Citations=3)
26. **Pleural transport physiology: insights from biological marker measurements in transudates.**
Apostolidou E, Tsilioni I, **Hatzoglou C**, Molyvdas PA, Gourgoulianis KI. **Open Respir Med J**. 5:70-72, 2011. (Citations=4)
27. **Postmortem image analysis of sheep cortical leptomeningeal space and vasculature: theoretical implications on brain surface dialysis.**
Filippidis A, S. Zarogiannis, V. Liakopoulos, K. Gourgoulianis, P.A. Molyvdas, **C. Hatzoglou**. **ASAIO J**. 57(5):388-394, 2011. (Impact Factor=2.494)
28. **Insulin-induced electrochemical changes in pleura are associated with the location within the pleural cavity.**
V.K. Kouritas, M. Ioannou, K.I. Gourgoulianis, P.A. Molyvdas, **C. Hatzoglou**. **Exp Clin Endocrinol Diabetes**. 119(4): 252-256, 2011. (Impact Factor=1.927, Citations=1)
29. **Effect of histamine on the electrophysiology of the human parietal pleura.**
V.K. Kouritas, A. Tsantsaridou, K. Tepetes, N. Tsilimingas, K.I. Gourgoulianis, P.A. Molyvdas, **C. Hatzoglou**. **Mol Cell Endocrinol**. 332(1-2): 271-276, 2011. (Impact Factor=3.693, Citations=8)
30. **Evidence for non genomic action of 17beta estradiol on transepithelial resistance of human fetal membranes.**
C. Verikouki, **C. Hatzoglou**, A.I. Zavos, K.I. Gourgoulianis, P.A. Molyvdas, A. Kallitsaris, I. E. Messinis. **J Endocrinol Invest**. 34(7): 510-514, 2011. (Impact Factor=3.439)
31. **Permeability alterations after surgical trauma in normal rabbit peritoneum.**
V.K. Kouritas, K. Tepetes, G. Christodoulides, M. Ioannou, M. Spyridakis, K.I. Gourgoulianis, P.A. Molyvdas, **C. Hatzoglou**. **Eur Surg Res** 45(2): 113-119, 2010. (Impact Factor=1.629, Citations=6)
32. **Insulin-induced electrophysiology changes in human pleura are mediated via its receptor.**
V.K. Kouritas, M. Ioannou, C.N. Foroulis, N. Desimonas, K. Evaggelopoulos, K.I. Gourgoulianis, P.A. Molyvdas, **C. Hatzoglou**. **Exp Diabetes Res**. 2010:853176, 2010. (Impact Factor=4.325, Citations=6)
33. **Dexamethasone acutely accelerates pleural fluid absorption in mice hydrothoraces.**
S. Zarogiannis, I. Psallidas, **C. Hatzoglou**, K.I. Gourgoulianis, I. Kalomenidis. **J Physiol Sci**. 60(4): 299-302, 2010. (Impact Factor=3.341, Citations=8)

34. **Role of electrolytes and glucose in the insulin-induced electrochemical effect in sheep pleura.**
V.K. Kouritas, **C. Hatzoglou**, K.I. Gourgoulianis, P.A. Molyvdas.
Exp Clin Endocrinol Diabetes 118(5): 328-332, 2010. (Impact Factor=1.927, Citations=3)
35. **Pleural electrophysiology alterations in spontaneous pneumothorax patients.**
V.K. Kouritas, C.N. Foroulis, M Ioannou, G. Kalafati, N. Tsilimingas, K.I. Gourgoulianis, P.A. Molyvdas, **C. Hatzoglou**.
Interact Cardiovasc Thorac Surg. 10(6):958-961, 2010. (Impact Factor=1.931, Citations=4)
36. **Insulin alters the permeability of sheep pleura.**
V.K. Kouritas, **C. Hatzoglou**, M. Ioannou, K.I. Gourgoulianis, P.A. Molyvdas.
Exp Clin Endocrinol Diabetes. 118(5): 304-309, 2010. (Impact Factor=1.927, Citations=8)
37. **Transmembrane resistance and histology of isolated sheep leptomeninges.**
A. Filippidis, S. Zarogiannis, M. Ioannou, K.I. Gourgoulianis, P.A. Molyvdas, **C. Hatzoglou**.
Neurol Res. 32(2): 205-208, 2010. (Impact Factor=1.449, Citations=3)
38. **Effect of cimetidine on the electrophysiologic profile of isolated visceral sheep peritoneum.**
V. Liakopoulos, S. Zarogiannis, P. Kourti, **C. Hatzoglou**, A. Karioti, S. Arampatzis, M. Giannopoulou, C. Musso, K.I. Gourgoulianis, P.A. Molyvdas, I. Stefanidis.
Adv Perit Dial. 25: 20-23, 2009. (Citations=2)
39. **Spironolactone increases permeability of visceral sheep peritoneum.**
Karioti A, **C. Hatzoglou**, S. Zarogiannis, T. Deligiorgi, P. Kourti, M. Giannopoulou, S Arampatzis, V. Liakopoulos, K.I. Gourgoulianis, P.A. Molyvdas, I. Stefanidis.
Adv Perit Dial. 25: 16-19, 2009. (Citations=3)
40. **Pleural electrophysiology variations according to location in pleural cavity.**
V.K. Kouritas, **C. Hatzoglou**, K.I. Gourgoulianis, P.A. Molyvdas.
Interact Cardiovasc Thorac Surg. 9(3): 391-394, 2009. (Impact Factor=1.931, Citations=8)
41. **Dexamethasone decreases the transmesothelial electrical resistance of the parietal and visceral pleura.**
S. Zarogiannis, T. Deligiorgi, I. Stefanidis, V. Liakopoulos, K.I. Gourgoulianis, P.A. Molyvdas, **C. Hatzoglou**.
J Physiol Sci. 59(4): 335-339, 2009. (Impact Factor=3.341, Citations=5)
42. **Rapid effect of dexamethasone on the permeability of visceral sheep peritoneum.**
A. Karioti, **C. Hatzoglou**, S. Zarogiannis, T. Deligiorgi, P. Kourti, V. Liakopoulos, M. Giannopoulou, K.I. Gourgoulianis, P.A. Molyvdas, I. Stefanidis.
Adv Perit Dial. 24: 2-6, 2008. (Citations=4)
43. **Human parietal pleura present electrophysiology variations according to location in pleural cavity.**
V.K. Kouritas, **C. Hatzoglou**, C.N. Foroulis, K.I. Gourgoulianis.
Interact Cardiovasc Thorac Surg. 7(4): 544-547, 2008. (Impact Factor=1.931, Citations=21)
44. **Rapid effect of progesterone on transmesothelial resistance of human fetal membranes: evidence for non-genomic action.**
C. Verikouki, **C. Hatzoglou**, K. Gourgoulianis, P.A. Molyvdas, A. Kallitsaris, I. Messinis.
Clin Exp Pharmacol Physiol. 35(2): 174-179, 2008. (Impact Factor=2.336, Citations=13)

45. **Effect of sodium-potassium pump inhibition by ouabain on the permeability of isolated visceral sheep peritoneum.**
S. Zarogiannis, V. Liakopoulos, **C. Hatzoglou**, P. Kourti, K. Vogiatzidis, S. Potamianos, T. Eleftheriadis, K. Gourgoulisanis, P.A. Molyvdas, I. Stefanidis.
Adv Perit Dial. 23: 43-47 2007. (Citations=8)
46. **Effect of Endothelin-1 on the transmesothelial resistance of isolated visceral sheep peritoneum.**
P. Kourti, S. Zarogiannis, V. Liakopoulos, **C. Hatzoglou**, M. Giannopoulou, I. Chronopoulou, P. R. Mertens, S. Potamianos, K. Gourgoulisanis, P.A. Molyvdas, I. Stefanidis.
Adv Perit Dial. 23: 38-42, 2007. (Citations=5)
47. **mu-Opiod stimulation of isolated parietal sheep peritoneum decreases peritoneal permeability in vitro.**
S. Zarogiannis, K. Vogiatzidis, **C. Hatzoglou**, V. Liakopoulos, S. Potamianos, T. Eleftheriadis, S. Dovas, P. Kourti, K. Gourgoulisanis, P.A. Molyvdas, I. Stefanidis.
Adv Perit Dial. 23: 34-37, 2007. (Citations=3)
48. **Low glucose level and pH alters the electrochemical function of human parietal pleura.**
V. Kouritas, **C. Hatzoglou**, C.N. Foroulis, A. Hevas, K.I. Gourgoulisanis, P.A. Molyvdas.
Eur Respir J. 30(2): 354-357, 2007. (Impact Factor=11.807, Citations=17)
49. **Amiloride sensitive sodium channels on the parietal human peritoneum: evidence by Ussing-type chamber experiments.**
I. Stefanidis, V. Liakopoulos, P. Kourti, S. Zarogiannis, A. Poultsidi, P.R. Mertens, M. Salmas, **C. Hatzoglou**, K Gourgoulisanis, PA Molyvdas.
ASAIO J. 53(3): 335-338, 2007. (Impact Factor=2.494, Citations=18)
50. **Development of an egg-white bioassay for monitoring biotin levels in urine and serum.**
S. Zarogiannis, V. Liakopoulos, **C. Hatzoglou**, K. Vogiatzidis, M. Salmas, I. Stefanidis, K. Gourgoulisanis, P.A. Molyvdas.
Anal Sci. 23(5): 593-595, 2007. (Impact Factor=1.618, Citations=1)
51. **Comparison of the electrophysiological properties of the isolated sheep costal and diaphragmatic parietal pleura.**
S. Zarogiannis, **C. Hatzoglou**, I. Stefanidis, M. Ioannou, E. Paraskeva, K. Gourgoulisanis, P.A. Molyvdas.
Clin Exp Pharmacol Physiol. 34(1-2): 129-131, 2007. (Impact Factor=2.336, Citations=20)
52. **The contribution of ascorbic acid and dehydroascorbic acid to the protective role of pleura during inflammatory reactions.**
E. Gogou, **C. Hatzoglou**, V. Chamos, S. Zarogiannis, K.I. Gourgoulisanis, P.A. Molyvdas.
Med Hypotheses. 68(4): 860-863, 2007. (Impact Factor=1.322, Citations=8)
53. **Inhibition by mercuric chloride of aquaporin-1 in the parietal sheep peritoneum: An electrophysiological study.**
V. Liakopoulos, S. Zarogiannis, **C. Hatzoglou**, P. Kourti, A. Poultsidi, T. Eleftheriadis, K.I. Gourgoulisanis, PA Molyvdas, I. Stefanidis.
Adv Perit Dial. 22: 7-10, 2006. (Citations=5)
54. **Effect of adrenaline on transepithelial resistance of isolated sheep pleura.**
S. Zarogiannis, **C. Hatzoglou**, I. Stefanidis, G. Matafia, K. Vogiatzidis, K. Gourgoulisanis, P.A. Molyvdas.

- Respir Physiol Neurobiol.** 28;150(2-3): 165-172, 2006. (Impact Factor=1.582, Citations=18)
55. **Mu-Opioid influence on transmesothelial resistance of isolated sheep pleura and parietal pericardium.**
K. Vogiatzidis, **C. Hatzoglou**, S. Zarogiannis, G. Matafia, K.I Gourgoulianis, P.A. Molyvdas.
Eur J Pharmacol. 20;530(3): 276-280, 2006. (Impact Factor=3.170, Citations=19)
56. **Influence of the sodium transport inhibition by amiloride on the transmesothelial resistance of isolated visceral sheep peritoneum.**
S. Zarogiannis, P. Kourti, **C. Hatzoglou**, V. Liakopoulos, A. Poultsidi, KI Gourgoulianis, PA Molyvdas, I. Stefanidis.
Adv Perit Dial. 21: 5-8, 2005. (Citations=17)
57. **Enhancement of the transmesothelial resistance of the parietal sheep peritoneum by epinephrine in vitro: Ussing-type chamber experiments.**
I. Stefanidis, S. Zarogiannis, **C. Hatzoglou**, V. Liakopoulos, P. Kourti, A. Poultsidi, P.R. Mertens, K Gourgoulianis, PA Molyvdas.
Artif Organs. 29(11): 919-922, 2005. (Impact Factor=2.379, Citations=16)
58. **Functional similarities between pleura and the renal proximal tubule - membrane and cellular considerations.**
K.I. Gourgoulianis, **C. Hatzoglou**, P.A. Molyvdas.
Med Hypotheses. 64(1): 83-85, 2005. (Impact Factor=1.322, Citations=2)
59. **Effect of adrenaline on electrophysiological profile of isolated visceral sheep peritoneum.**
S. Zarogiannis, I. Stefanidis, **C. Hatzoglou**, V. Liakopoulos, KI Gourgoulianis, PA Molyvdas.
Adv Perit Dial. 20: 23-26, 2004. (Citations=15)
60. **The major route for absorption of fluid from the pleural space.**
K.I. Gourgoulianis, **C. Hatzoglou**, P.A. Molyvdas.
Lymphology. 35(3): 97-98, 2002. (Impact Factor=1.921, Citations=12)
61. **Effect of amiloride in human and sheep parietal pleura.**
S. Sarkos, **C. Hatzoglou**, J. Dahabre, K.I. Gourgoulianis, P.A. Molyvdas.
Respir Physiol Neurobiol. 30;132: 233-237, 2002. (Impact Factor=1.582, Citations=34)
62. **Rapid effects of 17 β estradiol and progesterone on sheep visceral and parietal pleura via nitric oxide pathway.**
C. Hatzoglou, K.I. Gourgoulianis, A. Hatzoglou, E. Castanas, P.A. Molyvdas.
J Appl Physiol. 93:752-758, 2002. (Impact Factor=3.140, Citations=38)
63. **Effects of SNP, ouabain, and amiloride on electrical potential profile of isolated sheep pleura.**
C. Hatzoglou, K.I. Gourgoulianis, P.A. Molyvdas.
J Appl Physiol. 90 (4): 1565-1569, 2001. (Impact Factor=3.140, Citations=65)
64. **Antiproliferative and receptor binding properties of alpha- and beta- casomorphins in the T47D human breast cancer cell line.**
A. Hatzoglou, E. Bakogeorgou, **C. Hatzoglou**, P.M. Martin, E. Castanas.
Eur J Pharmacol. 29;310 (2-3): 217-223, 1996. (Impact Factor=3.170, Citations=62)
- Clinical Research Papers (Number: 23, Impact Factor: 28.9355, Citations: 232)**
1. **Risk Assessment for Self Reported Obstructive Sleep Apnea and Excessive Daytime Sleepiness in a Greek Nursing Staff Population.**

- Alexandropoulou A, Vavougiou GD, **Hatzoglou C**, Gourgoulisian KI, Zarogiannis SG. **Medicina** (Kaunas). 12;55(8), 2019. (Impact Factor=1.467)
2. **Mesothelioma Mortality Rates in Greece for the Period 2005-2015 Is Increased Compared to Previous Decades.**
Gogou E, **Hatzoglou C**, Zarogiannis SG, Malli F, Jagirdar RM, Gourgoulisian KI. **Medicina** (Kaunas). 30;55(8), 2019. (Impact Factor=1.467)
 3. **Chronic Obstructive Pulmonary Disease as a Main Factor of Premature Aging.**
Karametos I, Tsiboli P, Togousidis I, **Hatzoglou C**, Giamouzis G, Gourgoulisian KI. **Int J Environ Res Public Health**. 13;16(4), 2019. (Impact Factor=2.468)
 4. **Effects of varenicline therapy in combination with advanced behavioral support on smoking cessation and quality of life in inpatients with acute exacerbation of COPD, bronchial asthma, or community-acquired pneumonia: A prospective, open-label, preference-based, 52-week, follow-up trial.**
Politis A, Ioannidis V, Gourgoulisian KI, Daniil Z, **Hatzoglou C**. **Chron Respir Dis**. 15(2):146-156, 2018. (Impact Factor=2.885, Citations=6)
 5. **Ergospirometry Findings in Wind Instrument Players and Opera Singers.**
Ksinopoulou H, **Hatzoglou C**, Daniil Z, Gourgoulisian K, Karetsi H. **Int J Occup Environ Med**. 8(1):60-1, 2017. (Citations=1)
 6. **Respiratory function in vocal soloists, opera singers and wind instrument musicians.**
Ksinopoulou H, **Hatzoglou C**, Daniil Z, Gourgoulisian K, Karetsi H. **Med Lav**. 13;107(6):437-443, 2016. (Citations=1)
 7. **COPD patients' medical care and support in Greece during financial crisis.**
Mitonas G, Juvana A, Daniil Z, **Hatzoglou C**, Gourgoulisian KI. **Inter J Gen Med**. 10;9: 401-7, 2016. (Citations=3)
 8. **COPD characteristics and socioeconomic burden in Hellenic correctional institutions.**
Bania EG, Daniil Z, **Hatzoglou C**, Alexopoulos EC, Mitsiki E, Gourgoulisian KI. **Int J Chron Obstruct Pulmon Dis**. 12;11:341-349, 2016. (Impact Factor=3.274, Citations=3)
 9. **A Qualitative Content Analysis of Spirituality and Religiosity amongst Greek COPD Patients.**
E Tzounis, T Kerenidi, Z Daniil, **C Hatzoglou**, E Kotrotsiou, K Gourgoulisian **Religions**. 7(3):22, 2016. (Citations=6)
 10. **An initial investigation of smokers' urges to smoke and their exercise intensity preference: A mixed methods approach.**
N Zourbanos, A Hatzigeorgiadis, A Tsiami, Tzatzaki, K Georgakouli, E Manthou, M Goudas, A Jamurtas, **C Hatzoglou**, N Chatzisarantis, M Hassandra, Y Theodorakis. **Cogent Medicine**. 3: 1149043, 2016. (Citations=13)
 11. **Effects of smoking cessation on serum leptin and adiponectin levels.**
Kryfti M, Dimakou K, Toumbis M, Daniil Z, **Hatzoglou C**, Gourgoulisian KI. **Tob Induc Dis**. 3;13:30, 2015. (Impact Factor=1.9, Citations=13)
 12. **Psychological profile of Greek doctors: differences among five specialties.**
Pappas P, Gouva M, Gourgoulisian K, **Hatzoglou C**, Kotrotsiou E. **Psychol Health Med**. 24:1-9, 2015. (Impact Factor=1.603, Citations=6)
 13. **Assessment of health level and socio-economic characteristics of people working in the shipbuilding industry: a control group study.**

- Koulouri A, Roupa Z, Sarafis P, **Hatzoglou C**, Gourgoulianis K.
Glob J Health Sci. 9;7(2):38443, 2014. (Citations=2).
14. **Telemetric detection of chronic obstructive pulmonary disease and investigation of quality of life for people working in shipbuilding industry.**
Koulouri A, Gourgoulianis K, **Hatzoglou C**, Roupa Z.
Acta Inform Med. 22(5):315-319, 2014. (Citations=3)
 15. **Social Influence and Smoking Habit in Adolescent.**
A Vasilopoulos, K Gourgoulianis, C Hatzoglou, Z Roupa.
Health Science Journal. 9;2:5, 2015. (Citations=3)
 16. **Juvenile (age 13-18) smoking incidence determinants in Greece.**
Vasilopoulos A, Gourgoulianis K, **Hatzoglou C**, Roupa Z.
Int J Nurs Pract. 13;21(5):550-555, 2015. (Impact Factor=1.189, Citations=3).
 17. **Clinical phenotypes related to smoking cessation.**
M. Minas, E. Apostolidou, I. Goudouva, E. Makris, K. Gourgoulianis, **C. Hatzoglou.**
J Subst Abuse Treat. 44(3):288-294, 2013. (Impact Factor=2.542, Citations=2)
 18. **Two-year mortality of patients with COPD in primary health care: an observational study.** Minas M, Verrou-Katsarou I, Mystridou P, Apostolidou E, **Hatzoglou C**, Gourgoulianis KI.
Int J Gen Med 5:815-822, 2012. (Citations=14)
 19. **Prisoners and cigarettes or «imprisoned in cigarettes»? What helps prisoners quit smoking?**
E. Makris, K. Gourgoulianis, **Hatzoglou C.**
BMC Public Health. 12(1):508, 2012. (Impact Factor=2.567, Citations=17)
 20. **Comparison of a network of primary care physicians and an open spirometry programme for COPD diagnosis.**
V. Konstantikaki, K. Kostikas, M. Minas, G. Batavanis, Z. Daniil, K.I. Gourgoulianis, **C. Hatzoglou.**
Respir Med. 105(2): 274-281, 2011. (Impact Factor=3.237, Citations=28)
 21. **COPD prevalence and the differences between newly and previously diagnosed COPD patients in a spirometry program.**
M. Minas, **C. Hatzoglou**, E. Karetsi, A.I. Papaioannou, K. Tanou, P. Tsaroucha, E. Gogou, K.I.Gourgoulianis, K. Kostikas.
Prim Care Respir J. 19(4): 363-370, 2010. (Citations=58)
 22. **Body composition in severe refractory asthma: comparison with COPD patients and healthy smokers.**
M. Minas, A.I. Papaioannou, A. Tsaroucha, Z. Daniil, **C. Hatzoglou**, M. Sgantzos, K.I. Gourgoulianis, K. Kostikas.
PLoS One. 6;5(10): e 13233, 2010. (Impact Factor=2.766, Citations=17)
 23. **Surveillance study of vector species on board passenger ships, risk factors related to infestations.**
V.A. Mouchtouri, R. Anagnostopoulou, A. Samanidou-Voyadjoglou, K. Theodoridou, **C. Hatzoglou**, J. Kremastinou, C. Hadjichristodoulou.
BMC Public Health. 27(8): 100, 2008. (Impact Factor=2.567, Citations=33)
- Reviews Number: 4, Impact Factor: 9.463, Citations: 34**

1. **Mechanisms of engineered nanoparticle induced neurotoxicity in *Caenorhabditis elegans*.**
Sinis SI, Gourgoulialis KI, **Hatzoglou C**, Zarogiannis SG.
Environ Toxicol Pharmacol. 22(67):29-34, 2019. (Impact Factor=3.061)
2. **Carbon Nanotubes and Other Engineered Nanoparticles Induced Pathophysiology on Mesothelial Cells and Mesothelial Membranes.**
Sinis SI, **Hatzoglou C**, Gourgoulialis KI, Zarogiannis SG.
Front Physiol. 29(9):295, 2018. (Impact Factor=3.201, Citations=3)
3. **Physiology of pericardial fluid production and drainage.**
Vogiatzidis K, Zarogiannis SG, Aidonidis I, Solenov EI, Molyvdas PA, Gourgoulialis KI, **Hatzoglou C**.
Front Physiol. 18;6:62, 2015. (Impact Factor=3.201, Citations=31)
4. **The Effect Of Family And Social Environment On Smoking Behaviour In Adolescence.**
Z Roupa, A Vasilopoulos, **C Hatzoglou**, K Gourgoulialis, A Kefaliakos, EA Mechili, O Archangelidi, E Mentzakis, M Diomidous.
European Scientific Journal. 12;2:62-80, 2016.

Letters to the Editor (Number: 8, Impact Factor: 128.276, Citations: 27)

1. **Yellow nail syndrome chyloous pleural effusions: defective lymph valves involved?**
S. Zarogiannis, **C. Hatzoglou**, K.I. Gourgoulialis, P.A. Molyvdas.
Chest. 134(6): 1353, 2008. (Impact Factor=9.657, Citations=7)
2. **Environmental asbestos exposure alters the male: female ratio in patients with pleural mesothelioma.**
E. Gogou, T. Kerenidi, V. Chamos, **C. Hatzoglou**, K.I. Gourgoulialis.
Respirology. 13(6): 931, 2008. (Impact Factor=4.756)
3. **Existence of Na⁺-K⁺ ATPase in sheep visceral and parietal pleura.**
S. Zarogiannis, K.I. Gourgoulialis, P.A. Molyvdas, **C. Hatzoglou**.
Respir Physiol Neurobiol. 164(3): 289, 2008. (Impact Factor=1.773, Citations=2)
4. **Adrenergic influence on the permeability of sheep diaphragmatic parietal pleura**
S. Zarogiannis, **C. Hatzoglou**, I. Stefanidis, V. Liakopoulos, K. Gourgoulialis, P.A. Molyvdas.
Respiration. 74(1): 118-120, 2007. (Impact Factor=2.935, Citations=10)
5. **Lymphangioliomyomatosis.**
S. Zarogiannis, **C. Hatzoglou**, P.A. Molyvdas, K.I. Gourgoulialis.
Eur Respir J. 28(6): 1284, 2006. (Impact Factor=11.807, Citations=1)
6. **Role of human visceral pleura in pleural fluid turnover: Need for morfological evidence of lymphatic stomata.**
S. Zarogiannis, **C. Hatzoglou**, K.I. Gourgoulialis, P.A. Molyvdas.
Chin Med J. 5;119(17): 1495-1496, 2006. (Impact Factor=1.596, Citations=2)
7. **Pleural cavity exploitation in beta-agonist-treated ARDS patients.**
S. Zarogiannis, **C. Hatzoglou**, K.I. Gourgoulialis, P.A. Molyvdas.
Am J Respir Crit Care Med. 1;173(11): 1291, 2006. (Impact Factor=16.494)
8. **Hypertonic saline for cystic fibrosis.**
S. Zarogiannis, **C. Hatzoglou**, K.I. Gourgoulialis.
N Engl J Med. 354(17): 1848-1851, 2006. (Impact Factor=79.258, Citations=5)

Published Papers in Greek Peer-Review Journals

Total Number of Publications: 13

1 Editorial

8 Reviews

8 Basic Research Papers

Oral and Poster Presentations in International Congresses

104 presentations in Respiratory, Nephrology, Basic Research Science, and General Practice Conferences.

Oral and Poster Presentations in Greek Congresses

129 presentations in Respiratory, Nephrology, Basic Research, and General Practice Science Conferences.

Books

Co-authorship of a chapter in an International Book.

Co-authorship in nine chapters in Greek books.

Participation in the the editing of three International books in Greek.

Translation of two chapters of international books.

Participation in the authorship of a chapter in Conference Proceedings.

Invited Lectures and Coordination of Round Tables in National Meetings

Presided 41 Round Table Sessions and gave 96 Invited Lectures in the field of Basic and Clinical Respiratory Research, and in the field of COPD and Smoking.

CLINICAL WORK

Established and directed the Smoking Cessation Center of the Department of Respiratory Medicine since 2004. The Smoking Cessation Center accepts patients one day per week with a yearly turnover of approximately 400 visits. Additionally, I coordinated the training of health related professionals for the establishment of a Smoking Cessation Center. In addition to the above I coordinated for 5 years (2006-2010, and 2014) the Community Program for the screening of the general population as well as the high risk population of Thessaly in terms of COPD. The Program was implemented by the Department of Respiratory Medicine, University of Thessaly, Greece.

ADMINISTRATIVE WORK

- 2019-Σήμερα Substitute representative member of the Research Committee and Management of the Special Account of Research Funds, of the Department of Nursing of the University of Thessaly.
- 2019-Σήμερα Member of the Interim Assembly of the Department of Nursing of the University of Thessaly.
- 2018 Member of the Committee for the development of Student Logbook of taught courses of the Department of Medicine of the University of Thessaly.
- 2018-Σήμερα Member of the Scientific Committee of the University of Thessaly Publications.
- 2014-2017 Member of the General Assembly of the Faculty of Medicine, University of Thessaly.
- (2007-2009)
- (2003-2005)
- 2011-Present Coordinator of the Respiratory Disease Working Group of the Hellenic Society for Primary Healthcare Research and Continuing Education.

- 2009-Present Member of the Board of Directors of the Master of Science in «Primary Health Care» Department of Medicine, University of Thessaly.
- 2009-Present Member of Financial Committee of the Master of Science in «Primary Health Care» Department of Medicine, University of Thessaly.
- 2009-Present Member of Ethics Committee of the Master of Science in «Primary Health Care» Department of Medicine, University of Thessaly.
- 2009-Present Member of the “Anti-Smoking” Working Group of the Hellenic Thoracic Society.
- 2007-Present Member of the “Pleural Diseases” Working Group of the Hellenic Thoracic Society.
- 2005-Present Member of the Thessalian Chapter of the Hellenic Society of General Practice.
- 2004-Present Establishment and management of the Smoking Cessation Center. Department of Respiratory Medicine, University Hospital of Larissa.
- 2003-Present Group Leader: Biological Membrane Permeability Research Group, Department of Physiology, Faculty of Medicine, University of Thessaly.
- 2003-Present Organization of 5 scientific meetings and member of the organizing or scientific committee in 18 Greek congresses.
- 2004-2016 Deputy Coordinator of the General Practice Residency, University Hospital of Larissa.
- 2004-2006 Member of the Research Committee of the Hellenic Society of General Practice.
- 2001-2002 Establishment of Prevention Clinic of the Greek Agricultural Bank, Chapter of Larissa.